 GARDEN CITY, N.Y., Feb. 08, 2022 GLOBE NEWSWIRE -- Beyond Air, Inc. NASDAQ: XAIR, a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide NO for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide UNO for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, is scheduled to participate in two upcoming investor conferences in March 2022. 